Venture capital fund
Venture fund commercialising biomedical research into medical products
Melbourne, VIC
Every published round Medical Research Commercialisation Fund took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies Medical Research Commercialisation Fund has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
Fund closes reported for Medical Research Commercialisation Fund, as distinct from the investments it has made.
Companies Medical Research Commercialisation Fund has backed that another company then bought. An exit for the holding, not a deal Medical Research Commercialisation Fund did.
| Name | Role | Sources |
|---|---|---|
| Dr Chris Nave | Principal Executive (former) | Brandon Capital portfolio, GBS Ventures |
| Dr Simon Wilkins | Head of Operations | Brandon Capital portfolio |
Stories naming Medical Research Commercialisation Fund. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Brandon Capital's blog interviews Denteric's operating chief about its gingipain-targeting therapy for periodontitis, trial progress, and its origins in University of Melbourne oral health research.
A profile of Brandon Capital partner Chris Smith, tracing his path from immunology research and a Cambridge postdoc into biotech investing, with resilience lessons drawn from equestrian sport and companies Aravax and ENA Respiratory.
Drug developer ENA Respiratory reports positive Phase 2a results for its INNA-051 nasal immunomodulator against influenza, with its Series A backed by Brandon Capital managed funds, the Minderoo Foundation and Uniseed.
Cancer biotech Amaroq Therapeutics appointed four experts to its advisory board as it moves toward clinical trials; the New Zealand company's backers include Brandon Capital, which reports $14m invested to date.
New Zealand biotech Amaroq Therapeutics reported early progress toward clinical trials and appointed four leading scientists to its scientific advisory board, strengthening its lncRNA cancer therapy programme.
Case study on how CSIRO's bioinformatics teams independently validated the cancer-target findings of Amaroq Therapeutics, a New Zealand biotech whose $14m seed round was funded by the Brandon Capital-managed MRCF and others.
New Zealand cancer biotech Amaroq Therapeutics had its lncRNA drug targets independently validated by CSIRO, according to this profile, which also recalls its $14 million seed round and support from Callaghan Innovation.
The MRCF, managed by publisher Brandon Capital, has launched a government-funded national biotech incubator with committed funding, and appointed a new Head of Operations, with applications now open for its first intake.
University of Queensland spin-out Q-Sera has banked $900,000 from MRCF and Uniseed to develop snake venom-based blood collection tubes; the piece also recalls Vaxxas's $15 million round.
Fibrotech Therapeutics raised $3 million in Series A backing from Brandon Capital-managed funds MRCF, BBF1 IIF and Uniseed to advance fibrosis drug FT011 through Phase Ib trials.
Biotech Cincera Therapeutics debuts with A$7 million in committed venture backing provided by the Medical Research Commercialisation Fund.
Denteric, a biotech spun out of an oral health research program, has raised $14 million for a gum disease vaccine, in a round led by the Biomedical Translation Fund with CSL also taking part.
Also denteric.com